IsoRay, Inc. (ISR)

Market Cap	54.26M
Revenue (ttm)	9.95M
Net Income (ttm)	-9.10M
Shares Out	142.07M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,172
Open	0.385
Previous Close	0.382
Day's Range	0.37 - 0.406
52-Week Range	0.19 - 0.51
Beta	1.19
Analysts	Buy
Price Target	1.02 (+164.5%)
Earnings Date	Nov 10, 2022

About ISR

Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based i...

• Industry: Biotechnology
• Founded: 1983
• CEO: Lori Woods
• Employees: 66
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: ISR

Financial Performance

In 2022, IsoRay's revenue was $10.80 million, an increase of 7.38% compared to the previous year's $10.05 million. Losses were -$7.27 million, 114.7% more than in 2021.

Analyst Forecast

According to 6 analysts, the average rating for ISR stock is "Buy." The 12-month stock price forecast is 1.02, which is an increase of 164.52% from the latest price.

Price Target

$1.02

(164.52% upside)

Analyst Consensus: Buy